Boston Advisors’s Acorda Therapeutics ACOR Stock Holding History

Boston Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-152	Closed	-$383K	–	671
2017 Q1	$383K	Buy	+152	New	+$438K	0.01%	520

Other funds holding ACOR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boston Advisors's ACOR Position: Q2 2017 in Review

Boston Advisors sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 152 shares — an estimated $383K sold.

Boston Advisors first reported a position in ACOR in Q1 2017 and held it in 1 quarter. The position peaked at $383K in Q1 2017. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

Boston Advisors reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
Boston Advisors sold 152 Acorda Therapeutics shares in Q2 2017, an estimated $383K.
Boston Advisors first reported a position in Acorda Therapeutics in Q1 2017 and held it in 1 quarter.
Boston Advisors's Acorda Therapeutics position peaked at $383K in Q1 2017.
151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on Boston Advisors's 13F filing for Q2 2017, filed 25 Jul 2017.